226 related articles for article (PubMed ID: 28326864)
1. Role of the Notch signaling in cholangiocarcinoma.
Cigliano A; Wang J; Chen X; Calvisi DF
Expert Opin Ther Targets; 2017 May; 21(5):471-483. PubMed ID: 28326864
[TBL] [Abstract][Full Text] [Related]
2. Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
Gu Y; Xiao L; Ming Y; Zheng Z; Li W
Int J Oncol; 2016 May; 48(5):1868-76. PubMed ID: 26935808
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Notch signaling as a therapeutic approach for liver cancer.
Wu G; Wilson G; George J; Qiao L
Curr Gene Ther; 2015; 15(2):171-81. PubMed ID: 25537772
[TBL] [Abstract][Full Text] [Related]
4. Notch signalling pathway in development of cholangiocarcinoma.
Rauff B; Malik A; Bhatti YA; Chudhary SA; Qadri I; Rafiq S
World J Gastrointest Oncol; 2020 Sep; 12(9):957-974. PubMed ID: 33005291
[TBL] [Abstract][Full Text] [Related]
5. Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis.
Morell CM; Fiorotto R; Fabris L; Strazzabosco M
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):447-54. PubMed ID: 23806629
[TBL] [Abstract][Full Text] [Related]
6. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
[No Abstract] [Full Text] [Related]
7. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
Louis C; Edeline J; Coulouarn C
Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
[No Abstract] [Full Text] [Related]
8. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
Wu T
Biochim Biophys Acta; 2005 Jul; 1755(2):135-50. PubMed ID: 15921858
[TBL] [Abstract][Full Text] [Related]
9. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
[TBL] [Abstract][Full Text] [Related]
11. JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?
Smirnova OV; Ostroukhova TY; Bogorad RL
World J Gastroenterol; 2007 Dec; 13(48):6478-91. PubMed ID: 18161917
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine Changes in Cholangiocarcinoma Growth.
Sato K; Francis H; Zhou T; Meng F; Kennedy L; Ekser B; Baiocchi L; Onori P; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
Cells; 2020 Feb; 9(2):. PubMed ID: 32069926
[TBL] [Abstract][Full Text] [Related]
13. Regulatory Roles of the Notch Signaling Pathway in Liver Repair and Regeneration: A Novel Therapeutic Target.
Valizadeh A; Sayadmanesh A; Asemi Z; Alemi F; Mahmoodpoor A; Yousefi B
Curr Med Chem; 2021; 28(41):8608-8626. PubMed ID: 33874861
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of cholangiocarcinoma carcinogenesis.
Maemura K; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):754-60. PubMed ID: 24895231
[TBL] [Abstract][Full Text] [Related]
15. The molecular pathogenesis of cholangiocarcinoma.
Berthiaume EP; Wands J
Semin Liver Dis; 2004 May; 24(2):127-37. PubMed ID: 15192786
[TBL] [Abstract][Full Text] [Related]
16. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium.
Gentilini A; Pastore M; Marra F; Raggi C
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249019
[TBL] [Abstract][Full Text] [Related]
17. Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy.
Li L; Tang P; Li S; Qin X; Yang H; Wu C; Liu Y
Med Oncol; 2017 Sep; 34(10):180. PubMed ID: 28918490
[TBL] [Abstract][Full Text] [Related]
18. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
Høgdall D; Lewinska M; Andersen JB
Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
[TBL] [Abstract][Full Text] [Related]
19. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma.
Koprowski S; Sokolowski K; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
J Surg Res; 2015 Oct; 198(2):434-40. PubMed ID: 25890434
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
